| Abbreviations |
|
2 | (3) |
|
Table 1 Clinical Approach to Initial Choice of Antimicrobial Therapy |
|
|
5 | (71) |
|
Table 2 Recommended Antimicrobial Agents Against Selected Bacteria |
|
|
76 | (3) |
|
Table 3 Suggested Duration of Antibiotic Therapy for Selected Clinical Syndromes in Immunocompetent Patients |
|
|
79 | (1) |
|
Table 4A Antibacterial Activity Spectra |
|
|
80 | (10) |
|
4B Antifungal Activity Spectra |
|
|
88 | (1) |
|
4C Antiviral Activity Spectra |
|
|
89 | (1) |
|
Table 5A Treatment Options For Systemic Infection Due To Multi-Drug Resistant Gram-Positive Bacteria |
|
|
90 | (3) |
|
5B Antibacterial treatment: presumed or confirmed Enterobacterales producing extended-spectrum beta-lactamases (ESBL) |
|
|
90 | (1) |
|
5C Suggested specific antibacterial therapy: carbapenem-resistant Enterobacterales |
|
|
91 | (1) |
|
5D Suggested specific antibacterial therapy: highly resistant Pseudomonas aeruginosa |
|
|
92 | (1) |
|
Table 6 Suggested Management of Suspected or Culture-Positive Methicillin-Resistant S. aureus Infections |
|
|
93 | (1) |
|
Table 7 Antibiotic Hypersensitivity Reactions & Drug Desensitization Methods |
|
|
94 | (2) |
|
Table 8 Pregnancy Risk and Safety in Lactation |
|
|
96 | (5) |
|
Table 9A Selected Pharmacologic Features of Antimicrobial Agents |
|
|
101 | (16) |
|
9B Pharmacodynamics of Antibacterials |
|
|
113 | (1) |
|
9C Enzyme - and Transporter - Mediated Interactions of Antimicrobials |
|
|
113 | (4) |
|
Table 10A Antibiotic Dosage and Side-Effects |
|
|
117 | (19) |
|
10B Antimicrobial Agents Associated with Photosensitivity |
|
|
131 | (1) |
|
10C Aminoglycoside Once Daily and Multiple Daily Dosing Regimens |
|
|
132 | (1) |
|
10D Prolonged or Continuous Infusion Dosing of Selected Antibiotics |
|
|
133 | (2) |
|
10E Inhalation Antibiotics |
|
|
135 | (1) |
|
Table 11A Treatment of Fungal Infections |
|
|
136 | (15) |
|
11B Antifungal Drugs: Dosage, Adverse Effects, Comments |
|
|
148 | (3) |
|
Table 12A Treatment of Mycobacterial Infections |
|
|
151 | (14) |
|
12B Dosage and Adverse Effects of Antimycobacterial Drugs |
|
|
162 | (3) |
|
Table 13A Treatment of Parasitic Infections |
|
|
165 | (20) |
|
13B Dosage and Selected Adverse Effects of Antiparasitic Drugs |
|
|
180 | (3) |
|
13C Parasites that Cause Eosinophilia (Eosinophilia In Travelers) |
|
|
183 | (1) |
|
13D Sources for Hard-to-Find Antiparasitic Drugs |
|
|
184 | (1) |
|
Table 14A Antiviral Therapy |
|
|
185 | (37) |
|
14B Antiviral Drugs (Non-HIV) |
|
|
196 | (6) |
|
14C Antiretroviral Therapy (ART) in Treatment-Naive Adults (HIV/AIDS) |
|
|
202 | (11) |
|
14D Antiretroviral Drugs and Adverse Effects |
|
|
213 | (4) |
|
14E Hepatitis A & HBV Treatment |
|
|
217 | (1) |
|
14F HCV Treatment Regimens and Response |
|
|
218 | (4) |
|
Table 15A Antimicrobial Prophylaxis for Selected Bacterial Infections |
|
|
222 | (11) |
|
15B Antibiotic Prophylaxis to Prevent Surgical Infections in Adults |
|
|
224 | (3) |
|
15C Antimicrobial Prophylaxis for the Prevention of Bacterial Endocarditis in Patients with Underlying Cardiac Conditions |
|
|
227 | (1) |
|
15D Management of Exposure to HIV-1 and Hepatitis B and C |
|
|
228 | (3) |
|
15E Prevention of Selected Opportunistic Infections in Human Hematopoietic Cell Transplantation (HCT) or Solid Organ Transplantation (SOT) in Adults With Normal Renal Function |
|
|
231 | (2) |
|
Table 16 Pediatric dosing (Age 28 Days) |
|
|
233 | (6) |
|
Table 17A Dosage of Antimicrobial Drugs in Adult Patients with Renal Impairment |
|
|
239 | (18) |
|
17B No Dosage Adjustment with Renal Insufficiency by Category |
|
|
255 | (1) |
|
17C Antimicrobial Dosing in Obesity |
|
|
255 | (2) |
|
17D No Dosing Adjustment Required in Obesity |
|
|
257 | (1) |
|
Table 18 Antimicrobials and Hepatic Disease: Dosage Adjustment |
|
|
257 | (1) |
|
Table 19 Treatment of CAPD Peritonitis in Adults |
|
|
258 | (1) |
|
Table 20A Anti-Tetanus Prophylaxis, Wound Classification, Immunization |
|
|
259 | (2) |
|
20B Rabies Postexposure Prophylaxis |
|
|
260 | (1) |
|
Table 21 Selected Directory of Resources |
|
|
261 | (1) |
|
Table 22 Anti-Infective Drug-Drug Interactions |
|
|
262 | (38) |
|
Table 23 List of Generic and Trade Names |
|
|
300 | (2) |
| Index |
|
302 | |
